- Home
- NMIH vs KNSA Comparison
NMIH vs KNSA Comparison
Compare NMIH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMIH
- KNSA
- Stock Information
- Founded
- NMIH 2011
- KNSA 2015
- Country
- NMIH United States
- KNSA United Kingdom
- Employees
- NMIH N/A
- KNSA N/A
- Industry
- NMIH Property-Casualty Insurers
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- NMIH Finance
- KNSA Health Care
- Exchange
- NMIH Nasdaq
- KNSA Nasdaq
- Market Cap
- NMIH 2.8B
- KNSA 2.6B
- IPO Year
- NMIH 2013
- KNSA 2018
- Fundamental
- Price
- NMIH $37.06
- KNSA $40.96
- Analyst Decision
- NMIH Buy
- KNSA Strong Buy
- Analyst Count
- NMIH 6
- KNSA 7
- Target Price
- NMIH $42.17
- KNSA $49.71
- AVG Volume (30 Days)
- NMIH 409.1K
- KNSA 524.6K
- Earning Date
- NMIH 11-04-2025
- KNSA 10-28-2025
- Dividend Yield
- NMIH N/A
- KNSA N/A
- EPS Growth
- NMIH 9.56
- KNSA N/A
- EPS
- NMIH 4.79
- KNSA 0.47
- Revenue
- NMIH $692,208,000.00
- KNSA $597,973,000.00
- Revenue This Year
- NMIH N/A
- KNSA $62.63
- Revenue Next Year
- NMIH $5.15
- KNSA $29.93
- P/E Ratio
- NMIH $7.77
- KNSA $86.11
- Revenue Growth
- NMIH 8.86
- KNSA 55.68
- 52 Week Low
- NMIH $31.90
- KNSA $17.82
- 52 Week High
- NMIH $43.20
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- NMIH 52.21
- KNSA 63.72
- Support Level
- NMIH $35.44
- KNSA $37.61
- Resistance Level
- NMIH $38.04
- KNSA $41.27
- Average True Range (ATR)
- NMIH 0.92
- KNSA 1.66
- MACD
- NMIH 0.16
- KNSA 0.17
- Stochastic Oscillator
- NMIH 73.44
- KNSA 93.57
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.